MOBIDIAG
22.4.2020 06:02:09 CEST | Business Wire | Press release
Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has received emergency use authorization in Finland for its Novodiag® COVID-19 molecular diagnostic test for the rapid and fully automated detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). The Novodiag® COVID-19 is now available for use in Finland*. The process for obtaining emergency use authorization is now ongoing in Sweden, UK and France.
The Novodiag® COVID-19 assay allows qualitative determination of SARS-CoV-2 (orf1ab and N genes) directly from nasopharyngeal swabs. The test will operate using the Novodiag® rapid ‘sample-in, result-out’ system, allowing the fully automated detection of novel coronavirus in approximately 1 hour. In addition, Novodiag® has a closed system which ensures the protection of laboratory staff and healthcare professionals from possible contamination. The user-friendly nature of the system means that the Novodiag® system can also be used in high risk and hard to reach areas without the need for highly trained personnel.
This new test complements the emergency use test, Amplidiag® COVID-19 *, which is suitable for high-throughput screening, launched on 14 April 2020 . This test is now available in Finland and routinely used in the main Finnish clinical laboratories as well as in France where it has been validated by the National Center of Reference – Institut Pasteur.
Due to the high demand for diagnostic devices and tests globally, Mobidiag has ensured that its supply chain and manufacturing capabilities are robust and able to support its customers. This includes for example the sourcing and acquisition of various consumables to cover the complete workflow from sample collection to the results (e.g. inhouse production of enzymes, the development of our proprietary mNAT™ sample buffer and collection tubes).
Tuomas Tenkanen, CEO of Mobidiag, said, “The coronavirus pandemic is a global challenge that needs all parts of industry to respond with innovative solutions for multiple settings. Early detection of COVID-19 infections is critical in supporting clinical decisions to efficiently manage epidemiological and infection control measures to isolate patients in a timely manner and to globally improve patient care. At Mobidiag, we have harnessed our existing technologies and expertise, including supply chain management and manufacturing, to rapidly develop and supply two coronavirus diagnostics tests, providing clinicians solutions suited to their own laboratory capacities. We are pleased that from today we are able to offer Novodiag® COVID-19 which can be used in smaller units without the need for highly trained personnel and Amplidiag® COVID-19 which can be used in larger laboratories for high-throughput testing”.
* Amplidiag® COVID-19 is now available in Finland and France as an emergency use test. Novodiag® COVID-19 is available in Finland only at this time. Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Please follow the recommended processes and guidance for your location if you believe you could be infected by SARS-CoV-2.
Notes to editors
About Mobidiag Ltd
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose fast, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005945/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nomios Expands Presence in Southern Europe with Leading Portuguese Cybersecurity Services Specialist Orbcom23.9.2026 16:30:00 CEST | Press release
Nomios, a pan-European specialist in cybersecurity services, announces the acquisition of Orbcom, a leading Portuguese provider of cybersecurity services and IT consulting solutions with about €15 million of yearly revenue and 80 FTEs. Orbcom is one of the few partners with Diamond Innovator status within the Palo Alto Networks NextWave Partner Program in Portugal and a key partner of Netskope, Infoblox and Arista. The acquisition marks another milestone in Nomios’ European expansion, establishing the Group’s first foothold in Portugal and further reinforcing its position as the trusted cybersecurity partner for organisations across Europe. Strengthening our security expertise with key vendor relationships Nomios supports organisations across Europe in securing their critical digital infrastructures, whether on-premise or cloud based. Nomios’ approach is structured around three core service pillars. Through its Consulting Services, the group provides strategic advisory and tailored sup
illumynt Expands Ohio Operations to Support Growing Demand for Advanced Technology Lifecycle Services23.9.2026 16:01:00 CEST | Press release
Expanded Columbus-area campus will provide approximately 200,000 square feet of operational and innovation capacity to support AI infrastructure, hyperscalers, OEMs and enterprise customers. illumynt, a technology-driven lifecycle management company specializing in advanced diagnostics, repair, component recovery and secure processing, today announced the expansion of its Columbus-area operations to approximately 200,000 square feet, significantly increasing the company’s capacity to support the rapidly evolving requirements of AI infrastructure, hyperscale data centers, OEMs and enterprise technology environments. The expanded campus will provide additional capacity to scale Talorem™, illumynt’s proprietary technology platform for advanced asset identification, diagnostics, repair, component recovery and lifecycle intelligence. The expansion will enable illumynt to further develop these capabilities while deploying them at greater operational scale. As AI infrastructure accelerates ha
Corient Expands to Cayman Islands with Acquisition of FortCay Family Office Advisory23.9.2026 15:00:00 CEST | Press release
Establishes Corient’s presence in a premier global wealth jurisdiction and enhances its expertise in serving families with complex cross-border needs Corient, the world’s largest multi-family office and non-bank wealth manager focused on ultra-high-net-worth and high-net-worth clients, today announced the addition of FortCay Family Advisory (“FortCay”), a Cayman Islands wealth manager and multi-family office. FortCay, founded by Billy Harty and Matt Houghton, serves 14 ultra-high-net-worth families representing approximately US$2.6 billion in client assets, providing comprehensive wealth management, estate planning and family office services. The acquisition establishes Corient in the Cayman Islands, a leading international financial center and important hub for private wealth, extending the firm’s reach in a strategically important market. “A meaningful share of the world’s most complex family wealth is structured and administered in the Cayman Islands,” said Kurt MacAlpine, Founding
GTN and Solidus Labs Announce Landmark Surveillance Partnership23.9.2026 15:00:00 CEST | Press release
GTN, the global fintech, and Solidus Labs, the category-definer in multidimensional market integrity, today announced a landmark partnership that deploys Solidus Labs' HALO platform across GTN's operations. Under the partnership, HALO is deployed across GTN's global order book, delivering integrated trade surveillance and transaction monitoring across equities, fixed income, derivatives, FX and digital/crypto assets. This means for brokers, banks, asset managers and fintechs, the era of surveillance as a barrier to market participation is over. Beyond GTN's internal compliance operations, this partnership introduces a surveillance layer that lets GTN's 500+ clients access dedicated HALO tenants through GTN's infrastructure. This embeds institutional-grade surveillance capabilities into the infrastructure that those firms already run their business on. Rather than each client independently procuring, integrating and running a surveillance stack, GTN's model lets firms across its institu
SS&C Technologies Unveils Portfolio of AI-Enabled Enhancements; Debuts Six-Part Agentic Blueprint Docuseries at SS&C Deliver23.9.2026 15:00:00 CEST | Press release
New AI-enabled solutions and enhancements roll out across SS&C’s financial services and healthcare businesses, alongside a six-part docuseries on the company’s own agentic AI transformation SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today unveiled a suite of next-generation solutions at its annual SS&C Deliver 2026 conference. More than 1,100 leaders from the financial services and healthcare industries gathered in Orlando, Florida, to learn how SS&C is optimizing business workflows with AI-enabled services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923521682/en/ A core technology set spanning wealth, retirement, alternatives and asset management is built on the SS&C AI Gateway governance platform. SS&C WorkHQ, the company’s award-winning agentic orchestration platform, enables interoperability across these solutions. SS&C also debuted the six-part The Blueprint: Customer Zero docuseries, a behind-the-scenes loo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom